Amikacin concentrations predictive of ototoxicity in multidrug-resistant tuberculosis patients

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 10, 2015, Pages 6337-6343

  Modongo, Chawangwa ^a,b   Pasipanodya, Jotam G ^c   Zetola, Nicola M ^a,b,d   Williams, Scott M ^e   Sirugo, Giorgio ^f   Gumboc, Tawanda ^c,g  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b BOTSWANA UPENN PARTNERSHIP   (Botswana)

^c UNIVERSITY OF TEXAS AT DALLAS   (United States)

^d UNIVERSITY OF BOTSWANA   (Botswana)

^e DARTMOUTH MEDICAL SCHOOL   (United States)

^f FATEBENEFRATELLI HOSPITAL   (Italy)

^g UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CYCLOSERINE; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; ETHIONAMIDE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; LEVOFLOXACIN; PYRAZINAMIDE; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADULT; ALGORITHM; AREA UNDER THE CURVE; ARTICLE; AUDIOMETRY; BOTSWANA; CLASSIFICATION AND REGRESSION TREE ANALYSIS; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; HEARING IMPAIRMENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MACHINE LEARNING; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; OTOTOXICITY; PEAK-TROUGH FLUCTUATION; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROBABILITY; RECEIVER OPERATING CHARACTERISTIC; TINNITUS; TREATMENT DURATION; CHEMICALLY INDUCED; CLINICAL DECISION MAKING; HEARING LOSS, SENSORINEURAL; MICROBIOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ADULT; AMIKACIN; ANTITUBERCULAR AGENTS; AREA UNDER CURVE; AUDIOMETRY; CLINICAL DECISION-MAKING; FEMALE; HEARING LOSS, SENSORINEURAL; HUMANS; MACHINE LEARNING; MALE; MIDDLE AGED; PROBABILITY; ROC CURVE; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84942935430     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01050-15     Document Type: Article

References (32)

1. Dheda K, Gumbo T, Gandhi NR, Murray M, Theron G, Udwadia Z, Migliori GB, Warren R. 2014. Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis. Lancet Respir Med 2:321-338. http://dx.doi.org/10.1016/S2213-2600 (14) 70031-1.
2. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, Zeller K, Andrews J, Friedland G. 2006. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368:1575-1580. http://dx.doi.org/10.1016/S0140-6736 (06) 69573-1.
3. World Health Organization. 2010. Multidrug and extensively drugresistant TB (M/XDR-TB): global report on surveillance and response. WHO/HTM/TB/2010.3. 2010. World Health Organization, Geneva, Switzerland.
4. Falzon D, Jaramillo E, Schunemann HJ, Arentz M, Bauer M, Bayona J, Blanc L, Caminero JA, Daley CL, Duncombe C, Fitzpatrick C, Gebhard A, Getahun H, Henkens M, Holtz TH, Keravec J, Keshavjee S, Khan AJ, Kulier R, Leimane V, Lienhardt C, Lu C, Mariandyshev A, Migliori GB, Mirzayev F, Mitnick CD, Nunn P, Nwagboniwe G, Oxlade O, Palmero D, Pavlinac P, Quelapio MI, Raviglione MC, Rich ML, Royce S, Rusch-Gerdes S, Salakaia A, Sarin R, Sculier D, Varaine F, Vitoria M, Walson JL, Wares F, Weyer K, White RA, Zignol M. 2011. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 38:516-528. http://dx.doi.org/10.1183/09031936.00073611.
5. Ambrose PG, Bhavnani SM, Rubino CM, Louie A, Gumbo T, Forrest A, Drusano GL. 2007. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 44:79-86. http://dx.doi.org/10.1086/510079.
6. Gumbo T, Angulo-Barturen I, Ferrer-Bazaga S. 2015. Pharmacokineticpharmacodynamic and dose-response relationships of antituberculosis drugs: recommendations and standards for industry and academia. J Infect Dis 211(Suppl 3):S96-S106. http://dx.doi.org/10.1093/infdis/jiu610.
7. Louie A, Kaw P, Liu W, Jumbe N, Miller MH, Drusano GL. 2001. Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection. Antimicrob Agents Chemother 45:845-851. http://dx.doi.org/10.1128/AAC.45.3.845-851.2001.
8. Oleson FB, Jr, Berman CL, Kirkpatrick JB, Regan KS, Lai JJ, Tally FP. 2000. Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob Agents Chemother 44:2948-2953. http://dx.doi.org/10.1128/AAC.44.11.2948-2953.2000.
9. Pasipanodya JG, McIlleron H, Burger A, Wash PA, Smith P, Gumbo T. 2013. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis 208:1464-1473. http://dx.doi.org/10.1093/infdis/jit352.
10. Pasipanodya JG, Gumbo T. 2010. Clinical and toxicodynamic evidence that high-dose pyrazinamide is not more hepatotoxic than the low doses currently used. Antimicrob Agents Chemother 54:2847-2854. http://dx.doi.org/10.1128/AAC.01567-09.
11. Chigutsa E, Pasipanodya JG, Visser ME, van Helden PD, Smith PJ, Sirgel FA, Gumbo T, McIlleron H. 2015. Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis. Antimicrob Agents Chemother 59:38-45. http://dx.doi.org/10.1128/AAC.03931-14.
12. Gumbo T, Siyambalapitiyage Dona CS, Meek C, Leff R. 2009. Pharmacokineticspharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs. Antimicrob Agents Chemother 53:3197-3204. http://dx.doi.org/10.1128/AAC.01681-08.
13. Modongo C, Sobota RS, Kesenogile B, Ncube R, Sirugo G, Williams SM, Zetola NM. 2014. Successful MDR-TB treatment regimens including amikacin are associated with high rates of hearing loss. BMC Infect Dis 14:542. http://dx.doi.org/10.1186/1471-2334-14-542.
14. Black RE, Lau WK, Weinstein RJ, Young LS, Hewitt WL. 1976. Ototoxicity of amikacin. Antimicrob Agents Chemother 9:956-961. http://dx.doi.org/10.1128/AAC.9.6.956.
15. Steinberg D, Colla P. 1995. CART: tree-structured non-parametric data analysis. Salford Systems, San Diego, CA.
16. Breiman L, Friedman J, Stone CJ, Olshen RA. 1984. Classification and regression trees. Chapman and Hall/CRC, Boca Raton, FL.
17. Gumbo T, Chigutsa E, Pasipanodya J, Visser M, van Helden PD, Sirgel FA, McIlleron H. 2014. The pyrazinamide susceptibility breakpoint above which combination therapy fails. J Antimicrob Chemother 69:2420-2425. http://dx.doi.org/10.1093/jac/dku136.
18. Domke I, Cremer P, Huchtemann M. 2000. Therapeutic drug monitoring on COBAS INTEGRA 400-evaluation results. Clin Lab 46:509-515.
19. D'Argenio DZ, Schumitzky A, Wang X. 2009. ADAPT 5 user's guide: pharmacokinetic/pharmacodynamic systems analysis software. Biomedical Simulations Resource, Los Angeles, CA.
20. Hall RG, Swancutt MA, Meek C, Leff RD, Gumbo T. 2012. Ethambutol pharmacokinetic variability is linked to body mass in overweight, obese, and extremely obese people. Antimicrob Agents Chemother 56:1502-1507. http://dx.doi.org/10.1128/AAC.05623-11.
21. Breiman L. 1996. Technical note: some properties of splitting criteria. Machine Learning 24:41-47.
22. Kim H, Loh WY. 2001. Classification trees with unbiased multiway splits. J Am Stat Assoc 88:457-467.
23. Sturdy A, Goodman A, Jose RJ, Loyse A, O'Donoghue M, Kon OM, Dedicoat MJ, Harrison TS, John L, Lipman M, Cooke GS. 2011. Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice. J Antimicrob Chemother 66:1815-1820. http://dx.doi.org/10.1093/jac/dkr221.
24. Javadi MR, Abtahi B, Gholami K, Safari MB, Tabarsi P, Salamzadeh J. 2011. The incidence of amikacin ototoxicity in multidrug-resistant tuberculosis patients. Iran J Pharm Res 10:905-911.
25. Peloquin CA, Berning SE, Nitta AT, Simone PM, Goble M, Huitt GA, Iseman MD, Cook JL, Curran-Everett D. 2004. Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. Clin Infect Dis 38:1538-1544. http://dx.doi.org/10.1086/420742.
26. Thein P, Kalinec GM, Park C, Kalinec F. 2014. In vitro assessment of antiretroviral drugs demonstrates potential for ototoxicity. Hear Res 310:27-35. http://dx.doi.org/10.1016/j.heares.2014.01.005.
27. Delattre IK, Musuamba FT, Nyberg J, Taccone FS, Laterre PF, Verbeeck RK, Jacobs F, Wallemacq PE. 2010. Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin exposure in critically ill septic patients. Ther Drug Monit 32:749-756. http://dx.doi.org/10.1097/FTD.0b013e3181f675c2.
28. Tod M, Lortholary O, Seytre D, Semaoun R, Uzzan B, Guillevin L, Casassus P, Petitjean O. 1998. Population pharmacokinetic study of amikacin administered once or twice daily to febrile, severely neutropenic adults. Antimicrob Agents Chemother 42:849-856.
29. Beaubien AR, Karpinski K, Ormsby E. 1995. Toxicodynamics and toxicokinetics of amikacin in the guinea pig cochlea. Hear Res 83:62-79. http://dx.doi.org/10.1016/0378-5955 (94) 00192-S.
30. Beaubien AR, Ormsby E, Bayne A, Carrier K, Crossfield G, Downes M, Henri R, Hodgen M. 1991. Evidence that amikacin ototoxicity is related to total perilymph area under the concentration-time curve regardless of concentration. Antimicrob Agents Chemother 35:1070-1074. http://dx.doi.org/10.1128/AAC.35.6.1070.
31. Aran JM, Chappert C, Dulon D, Erre JP, Aurousseau C. 1995. Uptake of amikacin by hair cells of the guinea pig cochlea and vestibule and ototoxicity: comparison with gentamicin. Hear Res 82:179-183. http://dx.doi.org/10.1016/0378-5955 (94) 00175-P.
32. Ibrahim S, Derde MP, Kaufman L, Clerckx-Braun F, Jacqmin P, Brulein V, Donnez J, Tulkens PM. 1990. Safety, pharmacokinetics and efficacy of once-a-day netilmicin and amikacin versus their conventional schedules in patients suffering from pelvic inflammatory disease. Ren Fail 12:199-203. http://dx.doi.org/10.3109/08860229009065564.